1. Home
  2. LNT vs UTHR Comparison

LNT vs UTHR Comparison

Compare LNT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alliant Energy Corporation

LNT

Alliant Energy Corporation

HOLD

Current Price

$72.18

Market Cap

18.3B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$500.47

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNT
UTHR
Founded
1917
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.3B
20.4B
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
LNT
UTHR
Price
$72.18
$500.47
Analyst Decision
Buy
Buy
Analyst Count
8
13
Target Price
$72.43
$520.00
AVG Volume (30 Days)
2.9M
307.6K
Earning Date
05-25-2026
05-28-2026
Dividend Yield
3.00%
N/A
EPS Growth
16.73
13.07
EPS
3.14
27.86
Revenue
$4,362,000,000.00
$1,483,300,000.00
Revenue This Year
$2.59
$8.56
Revenue Next Year
$6.32
$10.71
P/E Ratio
$22.78
$18.21
Revenue Growth
9.57
2.38
52 Week Low
$57.09
$266.98
52 Week High
$72.26
$537.19

Technical Indicators

Market Signals
Indicator
LNT
UTHR
Relative Strength Index (RSI) 69.83 56.75
Support Level $64.10 $463.06
Resistance Level $72.26 $516.36
Average True Range (ATR) 1.29 17.02
MACD 0.23 3.90
Stochastic Oscillator 98.69 50.18

Price Performance

Historical Comparison
LNT
UTHR

About LNT Alliant Energy Corporation

Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: